Special Issue: “Molecules against Alzheimer”
AbstractThis Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder and a leading cause of death worldwide. This Special Issue contains many interesting examples describing the design, synthesis, and pharmacological profiling of novel compounds that hit one or several key biological targets, such as cholinesterases, β-amyloid formation or aggregation, monoamine oxidase B, oxidative stress, biometal dyshomeostasis, mitochondrial dysfunction, serotonin and/or melatonin systems, the Wnt/β-catenin pathway, sigma receptors, nicotinamide phosphoribosyltransferase, or nuclear erythroid 2-related factor. The development of novel AD diagnostic agents based on tau protein imaging and the use of lithium or intranasal insulin for the prevention or the symptomatic treatment of AD is also covered in some articles of the Special Issue. View Full-Text
Share & Cite This Article
Decker, M.; Muñoz-Torrero, D. Special Issue: “Molecules against Alzheimer”. Molecules 2016, 21, 1736.
Decker M, Muñoz-Torrero D. Special Issue: “Molecules against Alzheimer”. Molecules. 2016; 21(12):1736.Chicago/Turabian Style
Decker, Michael; Muñoz-Torrero, Diego. 2016. "Special Issue: “Molecules against Alzheimer”." Molecules 21, no. 12: 1736.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.